Antibody Therapy Company Seeking FDA Emergency Use Authorization
Eli Lilly & Co. has now asked the United States drug regulators for an emergency use authorization for their experimental Covid-19 antibody therapy.
Recent data has shown that the use of the treatment has reduced hospitalizations. Eli Lilly & Co. is working with the Canadian company AbCellera Biologics Inc. to produce the therapy. These antibody therapies are considered some of the most prominent treatments for Covid-19. As we mentioned in a previous blog, these are considered a bridge to the vaccine so many companies are working on.
The emergency use request is for a single antibody treatment; however, the company is studying the effects of a two-antibody system. They will seek approval for this method in 2021. Results have shown that in people with mild to moderate symptoms, hospitalizations and ER visits were down when using their antibody treatment.
Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, said in the statement, “We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes. Lilly is diligently working with regulators around the world to make these treatments available.”
The number of doses will be much smaller than the vaccine plans, with only 100,000 available in October.
Be sure to check back with the ABN Blog for updates.